James Sheridan - Integrum Head EMEA
| INTEG-B Stock | SEK 18.45 0.15 0.81% |
Insider
James Sheridan is Head EMEA of Integrum AB Series
| Age | 58 |
| Phone | 46 3 17 60 10 60 |
| Web | https://www.integrum.se |
Integrum Management Efficiency
The company has return on total asset (ROA) of (0.0616) % which means that it has lost $0.0616 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0362 %, meaning that it generated $0.0362 on every $100 dollars invested by stockholders. Integrum's management efficiency ratios could be used to measure how well Integrum manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Ran Bronstein | Surgical Science Sweden | 59 | |
| MSc MSc | Oncopeptides AB | 53 | |
| Inbal MazorBadichi | Surgical Science Sweden | 54 | |
| Edward Holden | Swedencare publ AB | 42 | |
| Kristina Ingvar | Bonesupport Holding AB | 51 | |
| Ioanna Psychogiou | Swedencare publ AB | 38 | |
| Prof MD | Bonesupport Holding AB | 80 | |
| Pr MD | Oncopeptides AB | N/A | |
| Jenny Graflind | Swedencare publ AB | 47 | |
| Doron Zilberman | Surgical Science Sweden | 61 | |
| Michael Roth | Bonesupport Holding AB | 60 | |
| Jakob Lic | Oncopeptides AB | 51 | |
| Hkan Johansson | Bonesupport Holding AB | 60 | |
| Raquel Tosca | Swedencare publ AB | 49 | |
| Annika MBA | Oncopeptides AB | 57 | |
| Anders Larsson | Surgical Science Sweden | 50 | |
| Kristina Luthman | Oncopeptides AB | N/A | |
| Peter Nygren | Oncopeptides AB | 64 | |
| Emil Billbck | Bonesupport Holding AB | 53 | |
| Adv | Surgical Science Sweden | 55 | |
| Fergus MacLeod | Bonesupport Holding AB | 53 | |
Management Performance
| Return On Equity | 0.0362 | |||
| Return On Asset | -0.0616 |
Integrum AB Series Leadership Team
Elected by the shareholders, the Integrum's board of directors comprises two types of representatives: Integrum inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Integrum. The board's role is to monitor Integrum's management team and ensure that shareholders' interests are well served. Integrum's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Integrum's outside directors are responsible for providing unbiased perspectives on the board's policies.
| James Sheridan, Head EMEA | ||
| Karin MD, Chief Officer | ||
| Rickard Branemark, Director, Owner | ||
| AnnaTove Branemark, Chief Inc | ||
| Dennis Baecklund, Chief Officer | ||
| Thomas Dugan, Pres US |
Integrum Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Integrum a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0362 | |||
| Return On Asset | -0.0616 | |||
| Profit Margin | 0.07 % | |||
| Operating Margin | (0.22) % | |||
| Current Valuation | 619.71 M | |||
| Shares Outstanding | 17.57 M | |||
| Shares Owned By Insiders | 44.13 % | |||
| Shares Owned By Institutions | 24.12 % | |||
| Price To Book | 4.49 X | |||
| Price To Sales | 8.71 X |
Thematic Opportunities
Explore Investment Opportunities
Other Information on Investing in Integrum Stock
Integrum financial ratios help investors to determine whether Integrum Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Integrum with respect to the benefits of owning Integrum security.